In preclinical NSCLC models, such as patient-derived tumor xenograft models and cell lines, response rates to EGFR TKI therapy were improved by the addition of JAK or STAT3 inhibitors [138,139,140,141]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.